Motoko Inomata
- Toxicology top 2%
- Bioactive Compounds and Antitumor Agents 2
- Ophthalmology top 2%
- Ocular Oncology and Treatments 10
-
- Cancer-related Molecular Pathways 4
- Cancer Treatment and Pharmacology 4
-
- Cancer therapeutics and mechanisms 6
- TGF-β signaling in diseases 3
- Advanced biosensing and bioanalysis techniques 3
- RNA Interference and Gene Delivery 2
- Co-authors
- Akihiro KanekoFumiko FukuokaShoji ShibataAkio HoshiUshio SankawaHideaki OtsukaYutaka EbizukaY. ISOMURA
- Journals
- International Journal of Cancer (1 paper)Clinical Chemistry (1 paper)Investigative Ophthalmology & Visual Science (2 papers)
- Partner nations
- JapanUnited KingdomUnited States
In The Last Decade
Motoko Inomata
39 papers receiving 615 citations
Peers
Comparison fields: 5 of 78
- Toxicology 107
- Ophthalmology 196
- Radiology, Nuclear Medicine and Imaging 101
- Organic Chemistry 124
- Oncology 113
Countries citing papers authored by Motoko Inomata
This map shows the geographic impact of Motoko Inomata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Motoko Inomata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Motoko Inomata more than expected).
Fields of papers citing papers by Motoko Inomata
This network shows the impact of papers produced by Motoko Inomata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Motoko Inomata. The network helps show where Motoko Inomata may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Motoko Inomata, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 4 | |
| 2 | 2006 | 4 | |
| 3 | Signal Transduction Pathway of ActivinA in Retinoblastoma Cell Lines | 2005 | 2 |
| 4 | 2004 | 9 | |
| 5 | 2003 | 12 | |
| 6 | 2002 | 11 | |
| 7 | 1998 | 1 | |
| 8 | 1996 | 18 | |
| 9 | 1995 | 21 | |
| 10 | [Study on conservative treatment of retinoblastoma--effect of intravitreal injection of melphalan on the rabbit retina]. | 1995 | 45 |
| 11 | 1994 | 8 | |
| 12 | 1991 | 2 | |
| 13 | 1991 | 33 | |
| 14 | Improved colony formation of cultured retinoblastoma cells. | 1986 | 10 |
| 15 | 1985 | 23 | |
| 16 | 1981 | 2 | |
| 17 | 1978 | 11 | |
| 18 | 1978 | 16 | |
| 19 | 1974 | 12 | |
| 20 | 1965 | 3 |
About Motoko Inomata
Motoko Inomata is a scholar working on Ophthalmology, Toxicology and Biophysics, having authored 39 papers that have together received 658 indexed citations. Recurring topics across this work include Ocular Oncology and Treatments (10 papers), Cancer therapeutics and mechanisms (6 papers), Cancer-related Molecular Pathways (4 papers), Cancer Treatment and Pharmacology (4 papers), TGF-β signaling in diseases (3 papers), Advanced biosensing and bioanalysis techniques (3 papers), Bioactive Compounds and Antitumor Agents (2 papers) and RNA Interference and Gene Delivery (2 papers). The work is most often cited by research in Toxicology (107 citations), Ophthalmology (196 citations) and Radiology, Nuclear Medicine and Imaging (101 citations). Motoko Inomata has collaborated with scholars based in Japan, United Kingdom and United States. Frequent co-authors include Akihiro Kaneko, Fumiko Fukuoka, Shoji Shibata, Akio Hoshi, Ushio Sankawa, Hideaki Otsuka, Yutaka Ebizuka, Y. ISOMURA, Nagahiro Saijo and Akihiro Kaneko. Their work appears in journals such as International Journal of Cancer, Clinical Chemistry and Investigative Ophthalmology & Visual Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.